RNA (Atrium Therapeutics) Book Value per Share: $13.69 (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.65
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Book Value per Share?

Atrium Therapeutics RNA +2.61% 12 Book Value per Share is $13.69 as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's book value per share for the quarter that ended in Mar. 2026 was $13.69.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Atrium Therapeutics's current price is $13.65. Its book value per share for the quarter that ended in Mar. 2026 was $13.69. Hence, today's PB Ratio of Atrium Therapeutics is 1.00.

During the past 3 years, the highest P/B Ratio of Atrium Therapeutics was 1.22. The lowest was 0.86. And the median was 0.97.

Atrium Therapeutics  (NAS:RNA) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Atrium Therapeutics Book Value per Share Related Terms

Atrium Therapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Book Value per Share Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Book Value per Share
-4.13 -3.57 12.12

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Book Value per Share Get a 7-Day Free Trial -3.57 0.00 12.44 12.12 13.69

RNA vs CNTN, QTTB, TARA: Book Value per Share Comparison

For the Biotechnology subindustry, Atrium Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's PB Ratio falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Book Value per Share Calculation

Atrium Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(207.29-0.00)/17.11
=12.12

Atrium Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2026 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(234.10-0.00)/17.11
=13.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $13.69 mean?
Atrium Therapeutics (RNA) has a Book Value per Share of $13.69 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Book Value per Share too high?
Atrium Therapeutics' current Book Value per Share is $13.69. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Book Value per Share compare to CNTN and QTTB?
Atrium Therapeutics' Book Value per Share of $13.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Book Value per Share is $13.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Book Value per Share of $13.69. The current Book Value per Share is $13.69. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Book Value per Share is $13.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.65
Price